{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:24:04Z","timestamp":1793521444583,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008440","name":"International Parkinson and Movement Disorder Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.010","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:09:23Z","timestamp":1737533363000},"page":"341-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment of Motor Symptoms of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Luca","family":"Marsili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson's disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2024.12.010_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fneur.2018.00156","article-title":"Diagnostic criteria for Parkinson's disease: from james Parkinson to the concept of prodromal disease","volume":"9","author":"Marsili","year":"2018","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.010_bib3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.010_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120082","article-title":"Clinical milestones in Parkinson's disease: past, present, and future","author":"Marsili","year":"2022","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2024.12.010_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.553635","article-title":"Phenotype-agnostic molecular subtyping of neurodegenerative disorders: the Cincinnati cohort biomarker Program (CCBP)","volume":"12","author":"Sturchio","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/mds.29362","article-title":"Redefining bradykinesia","volume":"38","author":"Bologna","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0043-1763508","article-title":"Diagnostic uncertainties in tremor","volume":"43","author":"Marsili","year":"2023","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2024.12.010_bib8","article-title":"When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis","author":"Marsili","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2024.12.010_bib9","article-title":"Autoimmune encephalitis misdiagnosis in adults","author":"Flanagan","year":"2022","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.010_bib10","first-page":"2949","article-title":"Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications","volume":"267","author":"Merola","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.010_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ana.20814","article-title":"Treatment should not be initiated too soon in Parkinson's disease","volume":"59","author":"Aminoff","year":"2006","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","article-title":"Initiation of pharmacological therapy in Parkinson's disease: when, why, and how","volume":"19","author":"de Bie","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2024.12.010_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.14198","article-title":"Does delaying levodopa prevent motor complications in Parkinson's disease? A meta-analysis","author":"Ramanzini","year":"2024","journal-title":"Mov Disord Clin Prac"},{"issue":"Pt 10","key":"10.1016\/j.ncl.2024.12.010_bib14","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2024.12.010_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2024.12.010_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.irn.2017.01.002","article-title":"Treatment strategies in early Parkinson's disease","volume":"132","author":"Marsili","year":"2017","journal-title":"Int Rev Neurobiol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WCO.0000000000000113","article-title":"Treatment of early Parkinson's disease","volume":"27","author":"Pahwa","year":"2014","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/14737175.2022.2091436","article-title":"Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease","volume":"22","author":"Lenka","year":"2022","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5761\/atcs.cr.21-00052","article-title":"Thymoma-related stiff-person syndrome with successfully treated by surgery","volume":"28","author":"Sasaki","year":"2022","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00002826-199108000-00003","article-title":"Characterisation of the in\u00a0vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR)","volume":"14","author":"Wilding","year":"1991","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/08971900221151194","article-title":"A\u00a0review of levodopa formulations for the treatment of Parkinson's disease available in the United States","volume":"37","author":"Livingston","year":"2024","journal-title":"J\u00a0Pharm Pract"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/ern.11.195","article-title":"IPX066: a novel carbidopa-levodopa extended-release formulation","volume":"12","author":"Hauser","year":"2012","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","article-title":"Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial","volume":"12","author":"Hauser","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","article-title":"Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson's disease","volume":"20","author":"Pahwa","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib26","first-page":"837","article-title":"Conversion to IPX066 from standard levodopa formulations in advanced Parkinson's disease: experience in clinical trials","volume":"5","author":"Nausieda","year":"2015","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.010_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","article-title":"IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial","volume":"80","author":"Hauser","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/mds.29685","article-title":"Safety and efficacy of IPX203 in Parkinson's disease: the RISE-PD open-label extension study","volume":"39","author":"Espay","year":"2024","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40263-015-0242-2","article-title":"Long-term treatment with extended-release carbidopa-levodopa (IPX066) in early and advanced Parkinson's disease: a 9-month open-label extension trial","volume":"29","author":"Waters","year":"2015","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.010_bib30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","article-title":"A\u00a0randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease","volume":"31","author":"LeWitt","year":"2016","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib31","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1212\/CPJ.0000000000001043","article-title":"Biphasic (subtherapeutic) levodopa-induced respiratory dysfunction in Parkinson disease","volume":"11","author":"van de Wetering-van Dongen","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.ncl.2024.12.010_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2021.09.024","article-title":"ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study","volume":"91","author":"Giladi","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","article-title":"Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial","volume":"23","author":"Espay","year":"2024","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.010_bib34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.010_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrneurol.2015.122","article-title":"Restless legs syndrome-current therapies and management of augmentation","volume":"11","author":"Trenkwalder","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"20","key":"10.1016\/j.ncl.2024.12.010_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease Practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.010_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00406-006-0668-0","article-title":"Epidemiologic and clinical updates on impulse control disorders: a critical review","volume":"256","author":"Dell'Osso","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.010_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002826-199406000-00004","article-title":"Clinical usefulness of apomorphine in movement disorders","volume":"17","author":"Colosimo","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2024.12.010_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pbb.2016.10.003","article-title":"Selegiline induces a wake promoting effect in rats which is related to formation of its active metabolites","volume":"150-151","author":"Bundgaard","year":"2016","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1880","article-title":"Selegiline reduces daytime sleepiness in patients with Parkinson's disease","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Brain Behav"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.010_bib44","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.23954","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients","volume":"27","author":"Stocchi","year":"2012","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.010_bib46","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40263-023-01048-x","article-title":"Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Aboulatta","year":"2023","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44142-2","article-title":"Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system","volume":"13","author":"Asano","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"Ferreira","year":"2016","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","article-title":"Safety and efficacy of tolcapone in Parkinson's disease: systematic review","volume":"77","author":"Artusi","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ncl.2024.12.010_bib51","first-page":"85","article-title":"Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease","volume":"94","author":"Schwab","year":"1969","journal-title":"Trans Am Neurol Assoc"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.010_bib53","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/mdc3.13828","article-title":"Amantadine-induced craniofacial myoclonus: distinctive iatrogenic dysarthria in Parkinson's disease","volume":"10","author":"Lin","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2024.12.010_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113907","article-title":"Adenosine receptor antagonists: recent advances and therapeutic perspective","volume":"227","author":"Saini","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.010_bib55","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14656566.2023.2201374","article-title":"The role of istradefylline in the Parkinson's disease armamentarium","volume":"24","author":"M\u00fcller","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40261-015-0360-0","article-title":"Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis","volume":"36","author":"Leelakanok","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.010_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MCG.0000000000001961","article-title":"Management of gastrointestinal symptoms in Parkinson's disease: a comprehensive review of clinical presentation, workup, and treatment","volume":"58","author":"Pasricha","year":"2024","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.010_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1212\/WNL.0b013e3182477ec0","article-title":"\"On\" state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication","volume":"78","author":"Espay","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/mdc3.13445","article-title":"Conditions associated with on-state freezing of gait","volume":"9","author":"Sorrento","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2024.12.010_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106065","article-title":"\"Advanced\" Parkinson's disease: a review","volume":"123","author":"Aslam","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1590\/S0004-282X1995000500004","article-title":"[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease]","volume":"53","author":"Rocha","year":"1995","journal-title":"Arq Neuropsiquiatr"},{"issue":"4 Suppl 1","key":"10.1016\/j.ncl.2024.12.010_bib63","first-page":"S2","article-title":"The spectrum of levodopa-induced dyskinesias","volume":"47","author":"Fahn","year":"2000","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.010_bib64","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/mds.23667","article-title":"\"Silly walks\" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias","volume":"26","author":"R\u016f\u017ei\u010dka","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.010_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2019.07.030","article-title":"Dystonia in atypical parkinsonian disorders","volume":"66","author":"Marsili","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.010_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","article-title":"When the going gets tough: how to select patients with Parkinson's disease for advanced therapies","volume":"13","author":"Worth","year":"2013","journal-title":"Pract Neurol"},{"key":"10.1016\/j.ncl.2024.12.010_bib67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.parkreldis.2020.10.042","article-title":"Parkinson's disease advanced therapies - a systematic review: more unanswered questions than guidance","volume":"83","author":"Marsili","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"10.1016\/j.ncl.2024.12.010_bib68","first-page":"S65","article-title":"The choice between advanced therapies for Parkinson's disease patients: why, what, and when?","volume":"10","author":"Dijk","year":"2020","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.010_bib69","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garc\u00eda Ruiz","year":"2008","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib70","first-page":"946","article-title":"Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients","volume":"264","author":"Sesar","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ncl.2010.03.014","article-title":"Management of motor complications in Parkinson disease: current and emerging therapies","volume":"28","author":"Espay","year":"2010","journal-title":"Neurol Clin"},{"issue":"Suppl 4","key":"10.1016\/j.ncl.2024.12.010_bib72","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1353-8020(09)70844-2","article-title":"Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease","volume":"15","author":"Antonini","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2024.12.010_bib73","article-title":"Safety of levodopa-carbidopa intestinal gel treatment in patients with advanced Parkinson's disease receiving \u22652000\u00a0mg daily dose of levodopa","volume":"2020","author":"Zadikoff","year":"2020","journal-title":"Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib74","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/nmt-2018-0034","article-title":"Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry","volume":"9","author":"Poewe","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.ncl.2024.12.010_bib76","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.02.020","article-title":"Which patients discontinue? Issues on Levodopa\/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up","volume":"38","author":"Sensi","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.010_bib77","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1093\/brain\/awx252","article-title":"Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication","volume":"140","author":"Tinkhauser","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.010_bib78","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/awz344","article-title":"Evolving concepts on bradykinesia","volume":"143","author":"Bologna","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib79","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(12)70049-2","article-title":"Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation","volume":"11","author":"Fasano","year":"2012","journal-title":"Lancet Neurol"},{"issue":"Suppl 14","key":"10.1016\/j.ncl.2024.12.010_bib80","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1002\/mds.20962","article-title":"Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes","volume":"21","author":"Kleiner-Fisman","year":"2006","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.010_bib81","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.56.4.548","article-title":"Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD","volume":"56","author":"Volkmann","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2024.12.010_bib82","series-title":"Handbook of neurological therapy","first-page":"293","article-title":"Parkinson\u2019s disease","author":"Marsili CC","year":"2015"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.010_bib83","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1212\/WNL.0000000000000823","article-title":"Directional steering: a novel approach to deep brain stimulation","volume":"83","author":"Contarino","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.010_bib84","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/jnnp-2016-314500","article-title":"Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis","volume":"89","author":"Ho","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7800","article-title":"Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease: a systematic review and meta-analysis","volume":"2","author":"Artusi","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.ncl.2024.12.010_bib86","doi-asserted-by":"crossref","first-page":"e1395","DOI":"10.1212\/WNL.0000000000206771","article-title":"Prospective long-term follow-up of focused ultrasound unilateral subthalamotomy for Parkinson disease","volume":"100","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2024.12.010_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105431","article-title":"Magnetic Resonance-Guided focused ultrasound surgery for Parkinson's disease: a mini-review and comparison between deep brain stimulation","volume":"111","author":"Ko","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.010_bib88","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.molcel.2006.11.012","article-title":"Histidine phosphorylation of the potassium channel KCa3.1 by nucleoside diphosphate kinase B is required for activation of KCa3.1 and CD4 T\u00a0cells","volume":"24","author":"Srivastava","year":"2006","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.010_bib89","first-page":"273","article-title":"Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease","volume":"135","author":"Meng","year":"2020","journal-title":"J\u00a0Neurosurg"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.010_bib90","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1474-4422(13)70123-6","article-title":"Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease","volume":"12","author":"Petzinger","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib91","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1545968311416990","article-title":"Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up","volume":"26","author":"Frazzitta","year":"2012","journal-title":"Neurorehabil Neural Repair"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.010_bib92","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1053\/apmr.2002.34603","article-title":"Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial","volume":"83","author":"Miyai","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib93","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaneurol.2017.3517","article-title":"Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial","volume":"75","author":"Schenkman","year":"2018","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.010_bib94","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1515\/revneuro-2020-0011","article-title":"The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal","volume":"31","author":"Schirinzi","year":"2020","journal-title":"Rev Neurosci"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.010_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000500070","article-title":"A\u00a0randomized controlled trial to investigate the impact of tango argentino versus Tai Chi on quality of life in patients with Parkinson disease: a short report","volume":"26","author":"Poier","year":"2019","journal-title":"Complement Med Res"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.010_bib96","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.010_bib97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00002826-199304000-00003","article-title":"Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease","volume":"16","author":"Gervason","year":"1993","journal-title":"Clin Neuropharmacol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:56:23Z","timestamp":1750762583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861924001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0733861924001051"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.010","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Motor Symptoms of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}